期刊文献+

阿司匹林抵抗在2型糖尿病患者心血管事件中的影响研究 被引量:8

Effect of aspirin resistance on cardiovascular events in non-insulin-dependent diabetes mellitus patients
下载PDF
导出
摘要 目的探讨阿司匹林抵抗(AR)在2型糖尿病(T2DM)患者心血管事件中的影响。方法收集该院2006年6月至2010年9月,确诊为T2DM的患者496例,连续4周给予口服阿司匹林100mg/d,用光比浊法检测血小板聚集率,将患者分为AR组、阿司匹林半抵抗(ASR)组与阿司匹林敏感(AS)组,分别比较临床生化指标之间的差异,随访1~4年后比较发生不良心血管事件的差异。结果发生AR的占总人数的11.69%;发生ASR的占总人数的37.90%。女性在AR组与ASR组中人数较多(67.48%);AR组与ASR组患者较AS组的餐前空腹血糖高,差异有统计学意义(P<0.05);AR组糖化血红蛋白(HbA1c)、三酰甘油均高于AS组患者,差异有统计学意义(P<0.05)。3组间不良心血管事件发生率差异有统计学意义(P<0.05)。结论应对T2DM患者进行AR相关检测,推荐服用阿司匹林时应注意推荐的服用剂量,并且密切监视心血管事件的发生。 Objective To explore the effect of aspirin resistance on cardiovascular events in non-insulin-dependent diabetes melli- tus patients. Methods 496 patients with non-insulin-dependent diabetes mellitus received daily aspirin therapy (100rag/d) 4 weeks were recruited from Jun. 2006 to Sept. 2010. Platelet aggregation was measured by light transmission aggregometry. The patients were divided into three groups:aspirin resistance group, aspirin semi-resistance group and aspirin-sensitive group. The clinical bio- chemistry indications and the adverse cardiovascular events were collected. Results 11. 690% of patients were found to be resistant to aspirin therapy, and 37.90 % of patients to he aspirin semi-responders. There were 67.48 % female in aspirin resistance group and aspirin semi-responders. The preprandial glucose of group AR and ASR was higher than that of group AS(P〈0.05). The HbA1C and TG of group AR were higher than those of group AS(P〈0.05). There was statistically significant difference of the rate of car- diovascular events. Conclusion The measure of platelet aggregation should be taken in the diabetic mellitus patients and pay atten- tion on the dose of aspirin recommended. Particular attention is should also devote to the incidence of adverse cardiovascular events.
作者 武刚 程璐
出处 《重庆医学》 CAS CSCD 北大核心 2013年第21期2486-2488,共3页 Chongqing medicine
关键词 糖尿病 阿司匹林抵抗 不良心血管事件 diabetic mellitus aspirin resistance adverse cardiovascular events
  • 相关文献

参考文献16

  • 1Reusch JE. Diabetes, microvascular complications, and cardio- vascular complications:what is it about glucose[J]. J Clin Invest,2003,112(7) :986-988.
  • 2Haffner SM. Coronary heart disease in patients with dia- betes[J].N Engl J Meal,2000,342(14) :1040-1042.
  • 3Ong G, Davis TM, Davis WA. Aspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting: the Fremantle Diabetes study[J]. Diabetes Care, 2010,33 (2) : 317-321.
  • 4Jackson G. Aspirin: not currently for Primary Prevention in diabetes[J].Int J Clin Pract,2009,63(6) :831-832.
  • 5Ajjan R,Storey RF, Grant PJ. Aspirin resistance and dia- betes mellitus[J]. Diabetologia, 2008,51 ( 3 ) : 385-390.
  • 6钱荣立.关于糖尿病的新诊断标准与分型[J].中国糖尿病杂志,2000,8(1):5-6. 被引量:2313
  • 7Dillinger JG,Drissa A, Sideris G, et aI. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coro- nary artery disease[J]. Am Heart J, 2012, 164 (4) : 600- 606.
  • 8Di Minno MN, Lupoli R,Palmieri NM, et al. Aspirin re- sistance, platelet turnover, and diabetic angiopathy : a 2011 update[J]. Thromb Res,2012,129(3) :341-344.
  • 9Mardikar H,Deo D,Deshpande N. Variability in platelet response to a single daily dose of 150 mg enteric coated aspirin in a high risk population[J]. J Assoc Physicians India, 2008,56 : 321-324.
  • 10Natarajan A, Zaman AG, Marshall SM. Platelet hyperac- tivity in type 2 diabetes:role of antiplatelet agents[J]. Di- ab Vasc Dis Res,2008,5(2);138-144.

二级参考文献20

  • 1Anonymous.Collaborative overview of randomized trials of antiplatelet therapy-Ⅰ-Ⅲ[J].BMJ,1994,308(6921-6923):81106,159-168,235-246.
  • 2Helgason C M,Bolin K M,Hoff J A,et al.Development of aspirin resistance in persons with previous ischemic stroke[J].Stroke,1994,25:2331-2336.
  • 3Pappas J M,Westengard J C,Bull B S.Population variability in the effect of aspirin on platelet function:implication for clinical trials and therapy[J].Arch Pathol Lab Med,1994,118:801-804.
  • 4Grotemeyer K H,Scharafinski H W,Husstedt I W.Two-year follow-up of aspirin responder and aspirin non-responder:a pilot-study including 180 post-stroke patients[J].Thromb Res,1993,71:397-403.
  • 5Gum P A,Kotike-Marchant K,Poggio E D,et al.Profile and prevalence of aspirin resistance in patients with cardiovascular disease[J].Am J Cardiol,2001,88:230-235.
  • 6Gum P A,Kottke-Marchant K,Welsh P A,et al.A Prospective,blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease[J].J Am Coll Cardiol,2003,41:961-965.
  • 7Lee P Y,Chen W H,Ng W,et al.Low-dose aspirin increases aspirin resistance in patients with coronary artery disease[J].Am J Med,2005,118:723-727.
  • 8Valles J,Santos M T,Aznar J,et al.Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality:the effect of low-does is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity[J].Circulation,1998,97:350-355.
  • 9Patrono C.Prevention of myocardial infarction and stroke by aspirin:different mechanisms? Different dosage[J]?Thromb Res,1998,92:s7s12.
  • 10Taylor D W,Barnett H J,Haynes R B,et al.Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy:a randomized controlled trial.ASA and Carotid Endarterectomy(ACE) trial collaborators[J].Lancet,1999,353:2179-2184.

共引文献2345

同被引文献82

引证文献8

二级引证文献94

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部